Sarcoma News and Research

RSS

Scientists map the genetic landscape of drug resistance in cancers

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

18 Oct 2024

Diagnostic performance of GPT-4 in analyzing radiology findings from brain tumors

GPT-4 demonstrates diagnostic capabilities in brain radiology, achieving 73% accuracy for final diagnoses and 94% for differential diagnoses in recent research.

3 Oct 2024

UCLA Health researchers showcase advances in radiation oncology at ASTRO

UCLA Health Jonsson Comprehensive Cancer Center researchers and physicians who specialize in treating patients with radiation therapies will present data on the latest radiation oncology research and clinical trial results at the 66th annual American Society for Radiation Oncology (ASTRO) meeting in Washington D.C., Sept. 29 to Oct. 2.

27 Sep 2024

Study uncovers hidden proteins fueling heart disease and stroke

Researchers identified key proteins linked to cardiovascular disease, highlighting new targets for drug development using genetic and observational analyses in UK and China biobanks.

26 Sep 2024

UCLA develops largest collection of patient-derived organoids for sarcoma research

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.

20 Sep 2024

Clinical trial finds pomalidomide effective for treating rare bleeding disorder

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that affects 1 in 5,000 people worldwide.

18 Sep 2024

Breakthrough study sheds light on mechanisms behind the spread of gastric cancer to the peritoneum

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of cancer-related deaths worldwide, with over 1,000,000 new cases and close to 770,000 deaths each year.

13 Sep 2024

New research gives unprecedented view of colorectal cancer genetic makeup

Researchers provided a comprehensive genomic characterization of colorectal carcinoma, a type of cancer that starts in the colon or rectum, through whole-genome sequencing of 2,023 samples, identifying novel driver genes, molecular subgroups, and potential clinical implications.

15 Aug 2024

EZH2's role in cancer progression and therapy explored

Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

9 Aug 2024

Zebrafish model reveals how BCG vaccine triggers immune response in bladder cancer

Using zebrafish "Avatars", an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD student at the lab now working at the Universidad de las Américas in Quito, Ecuador – and colleagues studied the initial steps of the Bacillus Calmette-Guérin (BCG) vaccine's action on bladder cancer cells.

8 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

Discovery of Tr1 cells as a barrier to cancer immunotherapy offers new hope for treatment

Immunobiologists Robert Schreiber, PhD, (left) and Hussein Sultan, PhD, of Washington University School of Medicine in St. Louis, found that a subset of immune cells that normally puts the brakes on the immune system to prevent it from attacking the body's healthy cells inadvertently also dampens cancer immunotherapy.

7 Aug 2024

Researchers uncover immune system barrier to cancer treatment

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.

7 Aug 2024

Rising cancer rates in younger generations signal urgent need for early-life prevention strategies

A study in The Lancet Public Health reveals rising cancer incidence and mortality among younger US birth cohorts, indicating increased early-life carcinogenic exposure.

4 Aug 2024

FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.

2 Aug 2024

Study shows growing cancer burden in younger generations

A new large study led by researchers at the American Cancer Society (ACS) suggests incidence rates continued to rise in successively younger generations in 17 of the 34 cancer types, including breast, pancreatic, and gastric cancers.

1 Aug 2024

FDA approval of lifileucel: A milestone in tumor-infiltrating lymphocyte therapy for advanced melanoma

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy.

18 Jul 2024

40% of US cancer cases linked to lifestyle choices

Nearly 40% of cancer cases and 44% of cancer deaths in 2019 were due to modifiable risk factors, with cigarette smoking as the leading cause. This study highlights the potential to significantly reduce cancer burden through lifestyle changes.

14 Jul 2024

Study: 40% of cancer cases in the U.S. attributable to modifiable risk factors

A new study led by researchers at the American Cancer Society (ACS) finds four in 10 cancer cases and about one-half of all cancer deaths in adults 30 years old and older in the United States (or 713,340 cancer cases and 262,120 cancer deaths in 2019) could be attributed to modifiable risk factors, including cigarette smoking, excess body weight, alcohol consumption, physical inactivity, diet, and infections.

11 Jul 2024

Fibrinogen-like protein 1 plays dual role in liver regeneration and hepatocellular carcinoma recurrence

Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality globally, exhibits a dismal five-year survival rate of only 18%.

2 Jul 2024